Previous close | 37.20 |
Open | 0.00 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 134 |
Market cap | N/A |
Beta (5Y monthly) | 0.30 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies has launched Eroxon® in Sweden. Eroxon® is clinically proven and considered a breakthrough in treatment of erectile dysfunction for men and will be the first non-prescription treatment for erectile dysfunction in the Swedish market.
Navamedic ASA (OSE: Nava) will be presenting its 1st quarter 2024 results on Tuesday, April 30, 2024. The presentation will be held at Haakon VIIs gate 2 in Oslo and the event will start at 08.30 CET. A link to the webcast and the presentation will be available through the Navamedic web site on the following link: https://navamedic.com/investors/financial-results/
Navamedic (OSE: NAVA) is pleased to welcome new shareholders and delighted to see existing shareholders acquire a bigger stake following Ingerø Reiten Investment Company's (IRIC) sale of its entire 17.1 percent interest in the company.